They are provided strictly for research purposes only and must not be used outside approved laboratory protocols.
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
This is the version without DAC (Drug Affinity Complex) the DAC-bound long-acting form, which is a different compound, has a half-life of approximately 8 days
Researchers commonly compare several compounds within sleep-support and circadian rhythm studies depending on the goals of the laboratory model
[27] The connection between GSTP inhibition of the pro-apoptotic JNK pathway and the isozyme's overexpression in drug-resistant tumor cells may itself account for the tumor cells' ability to escape apoptosis mediated by drugs that are not substrates of GSTP